Today we shared positive updated lead-in data from our ongoing Phase 3 PEAK trail with bezuclastinib in combination with sunitinib in GIST patients. The data are being presented at #ASCO24. Read more here https://bit.ly/4dWlZlx.
Cogent Biosciences’ Post
More Relevant Posts
-
Join us for our oral presentation with Dr. Srinivas Tantravahi today at #ASH23 to discuss our new long-term selinexor data in treatment-naïve #Myelofibrosis patients. Click to see the latest data: https://bit.ly/41jiKi5
To view or add a comment, sign in
-
Are you looking to minimize patient burden while maximizing trial efficiency? #HomeTrial visits can make that happen. CROs, sponsors and sites can select the #ClinicalTrial approach that meets their specific needs and goals – offering a decentralized approach that offers an opportunity for a more diverse patient population. Learn more about home trials here → https://bit.ly/3FDChQs
To view or add a comment, sign in
-
Is upadacitinib safe and effective in patients with #psoriaticarthritis? 🔎Find out more in our article summarizing key findings from a real-world study, using prospective data from the UPJOINT trial 👇. https://loom.ly/J_wGFdY #PsA #PsoriaticArthritis #MedEd
To view or add a comment, sign in
-
#epeeps are often asked about the ability to discontinue AC post #AFib ablation. Current guideline directed recommendation is to continue solely based on CHADS2Vasc. This observational data suggest that we may be able to discontinue AC in lower risk patients: https://lnkd.in/esFNBX95 Awaiting RCT for further guidance on this frequently encountered issue.
To view or add a comment, sign in
-
// Patient associations/Industry: the key to a positive interaction // What rare disease patients and families want is a simpler life. Discover what makes the relationship between members of a patients’ association and a biotech company work so well in this interview! #kayentis #eCOA #clinicaltrials #raredisease #patientassociation
To view or add a comment, sign in
-
🔍 Discover the latest insights on uveitis frequency and risk factors in PsA patients! Explore Hijazi, et al.'s new publication through our comprehensive slide deck on the #IMIDForum. Keep yourself up to date and stay ahead in your clinical practice with our detailed slide decks: https://lnkd.in/eyyUGv2W #PsA #Uveitis #ClinicalInsights
To view or add a comment, sign in
-
Cardiologist, #HeartSuccess Program Builder Therapy & Technology Investigator Associate Professor of Cardiovascular Medicine Associate Editor, Journal of Cardiac Failure | Dad
🆕 #JACC state-of-the-art review highlights a shift toward a more tailored approach in the management of stable angina by performing a precise endotype diagnosis in patients with INOCA. https://lnkd.in/gy3ey8BC
To view or add a comment, sign in
-
📢 Groundbreaking Update in Diagnostics Assessment! 📢 For the first time, the IQWiG has completed a benefit assessment for a diagnostic in Germany. The evaluation revealed no additional benefit for the diagnostic tool under review. It will be seen which impact such assessments might have on the availability of latest diagnostics in Germany. Other reimbursement routes might still apply. 🔗 Read more about the assessment: https://lnkd.in/evaFTrWx #HealthcareInnovation #Diagnostics #IQWiG #BenefitAssessment #MedicalEvaluation #PatientCare #MArS #MarketAccess Copyright picture: © Ralf Baumgarten
To view or add a comment, sign in
-
van Vollenhoven et al. present new 5-year data from the SELECT-EARLY trial which highlight the superior efficacy of upadacitinib over methotrexate in RA patients. Patients on upadacitinib achieved higher remission rates and better structural joint protection, with 59.3% achieving remission compared to 43.3% with methotrexate. The study also reports higher exposure-adjusted adverse event rates per 100 patient-years with upadacitinb 15mg compared with 30mg, emphasising the importance of individual risk assessment. Stay informed and access the full summary of this important trial on the #IMIDForum now! 🔗https://ow.ly/Q1CA50Tr0z5 #RA #Upadacitinib #JAKi #ClinicalResearch #MT
To view or add a comment, sign in
-
🌟Post-Market Clinical Survey Data for CELOX™ Rapid🌟 CELOX™ Rapid, the haemostatic agent designed to save lives with its fast-acting formula, has demonstrated exceptional efficacy. Proven to achieve haemostasis after just one application, CELOX™ Rapid ensures peace of mind in emergencies. Real-world performance data reveals no adverse events, confirming CELOX™ Rapid as the safest and most effective solution for controlling bleeding. Equip yourself with the power of CELOX™ Rapid and be prepared to save lives when it matters most. Read the summary report for full details - https://bit.ly/446N9Rs
To view or add a comment, sign in
11,568 followers